Merus N.V. (MRUS)
Automate Your Wheel Strategy on MRUS
With Tiblio's Option Bot, you can configure your own wheel strategy including MRUS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRUS
- Rev/Share 0.793
- Book/Share 8.6372
- PB 6.0888
- Debt/Equity 0.003
- CurrentRatio 5.8597
- ROIC -0.4832
- MktCap 3916729653.0
- FreeCF/Share -3.4728
- PFCF -16.3412
- PE -13.0871
- Debt/Assets 0.0024
- DivYield 0
- ROE -0.4118
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MRUS | Piper Sandler | -- | Overweight | -- | $84 | Feb. 13, 2025 |
| Initiation | MRUS | Wells Fargo | -- | Overweight | -- | $91 | Feb. 7, 2025 |
News
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus
Published: June 11, 2025 by: Seeking Alpha
Sentiment: Positive
MRUS initially surged on superior interim trial data while BCAX tanked, but BCAX has since rebounded post-ASCO as investors reconsider the data and target market. BCAX targets the tougher HPV-negative head and neck cancer segment, representing 80% of cases, and boasts a higher complete response rate than MRUS. Despite analyst preference for MRUS, BCAX's durability argument and deep response rates could drive long-term value if validated in future studies.
Read More
Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
- 63% response rate observed among 43 evaluable patients - 79% overall survival rate at 12-months; 9 months median progression-free survival - Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass.
Read More
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Merus N.V. (MRUS) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $0.59 per share a year ago.
Read More
Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
Published: April 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation
Read More
Merus to Present at Upcoming Investor Conferences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Read More
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Read More
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Read More
About Merus N.V. (MRUS)
- IPO Date 2016-05-19
- Website https://www.merus.nl
- Industry Biotechnology
- CEO Dr. Sven Ante Lundberg M.D.
- Employees 260